Immunovant ACR20 Win Masks Sjogren's Exit, $722M Cash

Immunovant (Nasdaq: IMVT) said on 9 November 2026 that IMVT-1402 600 mg met the primary endpoint of ACR20 response at Week 28 in difficult-to-treat rheumatoid arthritis, hitting 92.5% versus 75.6% for placebo at a p-value of 0.0139. The company also reported cash and cash equivalents of $722.3 million as of 30 September 2026 and a quarterly net loss of $97.2 million, or $0.47 per share, against $126.5 million a year earlier.

Context — why the RA win and Sjogren's pullback matter now

The trial's Period 2 used a randomized withdrawal design after an open-label lead-in. Immunovant enrolled 170 participants in Period 1 to receive IMVT-1402 600 mg for 16 weeks. Only those meeting ACR20 response criteria at Weeks 14 and 16 advanced, leaving 117 participants randomized in Period 2 to 600 mg (n=40), 300 mg (n=36), or placebo (n=41).

The 300 mg arm failed to separate from placebo, with 75.0% maintaining ACR20 at Week 28 and a p-value of 0.9426. That divergence between doses is the central clinical finding of the quarter, and it shapes how the FDA registration conversation is likely to be framed.

Separately, the company said it is unlikely to advance IMVT-1402 beyond the ongoing, fully enrolled Phase 2 trial in Sjogren's disease, citing an evolving landscape and recent data in the field. The company did not disclose which specific competitor data informed that decision.

Immunovant remains a majority-owned subsidiary of Roivant (Nasdaq: ROIV). Both companies operate in a clinical-stage immunology segment where cash runway and pivotal-trial readouts drive valuation more than near-term revenue, since neither currently markets a product.

Data — what the numbers show

The ACR20 primary endpoint was supported by directional movement in secondary measures, though neither reached statistical significance. Least squares mean CDAI change was -0.3 for 600 mg versus +3.1 for placebo (p=0.1096). SDAI change was +0.1 for 600 mg versus +3.5 for placebo (p=0.1299). Lower values indicate improvement on both indices.

Exploratory ACR50 and ACR70 rates at Week 28 were 80.0% and 52.5% for 600 mg, against 56.1% and 36.6% for placebo. Nominal p-values were 0.0117 and 0.1674 respectively. Immunovant stated the trial was not powered to detect differences on these measures.

Metric	Q2 FY2027	Q2 FY2026
R&D expense	$85.0M	$114.2M
G&A expense	$19.1M	$17.5M
Net loss	$97.2M	$126.5M
Net loss per share	$0.47	$0.73

On a non-GAAP basis, R&D was $78.5 million and G&A was $12.4 million for the quarter. Non-GAAP net loss was $84.0 million versus $113.3 million a year earlier. The R&D decline was attributed to winding down batoclimab trials and timing of contract manufacturing costs.

For the six months ended 30 September 2026, R&D rose to $227.6 million from $215.4 million, while G&A fell to $36.8 million from $43.5 million. Net loss for the half was $250.5 million, or $1.22 per share, against $247.1 million, or $1.43 per share.

Analysis — what it means for biotech and FcRn peers

The dose-response split is the most consequential detail. A 600 mg win paired with a 300 mg miss narrows the commercial thesis toward a single high-dose regimen, which affects manufacturing scale, pricing architecture, and how payers may evaluate the product against existing RA biologics. Immunovant did not disclose planned pricing.

The Sjogren's pullback removes a pipeline indication from the forward story before Phase 2 data have been reported. That reduces the number of shots on goal but also trims future development spend, which is consistent with the lower quarterly R&D figure.

Safety data support the tolerability narrative. Immunovant reported no serious adverse events, no Grade 3 or higher treatment-emergent adverse events, and no discontinuations in any arm during Period 2. For a chronic autoimmune indication requiring long-term dosing, that profile matters as much as efficacy to prescribing specialists.

The counter-argument is statistical. The primary endpoint cleared at p=0.0139, but CDAI and SDAI missed significance, and ACR70 was not significant. A regulator could view the totality as a single positive endpoint rather than a consistent profile, which is why the FDA discussion timing carries outsized weight.

Positioning in clinical-stage immunology tends to cluster around binary readouts. With Graves' disease and myasthenia gravis data now guided to calendar 2027, IMVT holders are carrying event risk across a longer window than the RA result alone resolves.

Outlook — what to watch next

FDA discussions are planned for later this year to determine the path forward for the registrational program in difficult-to-treat RA. The company did not disclose a specific date or meeting format.

Topline data across potentially registrational trials of IMVT-1402 in Graves' disease and myasthenia gravis are expected in calendar year 2027. Chronic inflammatory demyelinating polyneuropathy topline is guided to calendar year 2028. All other clinical development timelines were described as on track.

The Sjogren's Phase 2 trial remains fully enrolled, and the company said it expects to complete it without advancing further in that indication. Roivant hosted a live conference call and webcast at 8:00 a.m. ET on 9 November 2026 to discuss the results.

Cash of $722.3 million is stated to provide runway to a potential commercial launch of IMVT-1402 in Graves' disease under the current operating plan. Share count stood at 206,785,540 common shares issued and outstanding.

Frequently Asked Questions

What does the 300 mg miss mean for Immunovant's RA program?

The 300 mg dose showed 75.0% ACR20 maintenance versus 75.6% for placebo, with a p-value of 0.9426 — no separation. Only the 600 mg dose beat placebo. That outcome points toward a single-dose registrational strategy, which simplifies the filing but removes any lower-dose commercial option the company might have pursued.

How does the Sjogren's decision change Immunovant's pipeline?

Immunovant said it is unlikely to advance IMVT-1402 beyond the ongoing, fully enrolled Phase 2 trial in Sjogren's disease, citing an evolving landscape and recent field data. The company did not name the competing data. The practical effect is fewer indications in development and lower future spending tied to that program.

Why did Immunovant's quarterly net loss narrow year over year?

Net loss fell to $97.2 million from $126.5 million, driven mainly by R&D dropping to $85.0 million from $114.2 million. The company attributed the decline to winding down batoclimab trials and the timing of contract manufacturing costs. G&A rose slightly to $19.1 million on higher pre-commercial investment.

Bottom Line

Immunovant cleared its RA primary endpoint at 600 mg only, and the Sjogren's pullback now makes FDA alignment the next binary event.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.